Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology
Darnatein, a subsidiary of OSR Holdings (NASDAQ: OSRH), has secured a patent in China for its innovative protein-based osteoarthritis treatment technology. The patent covers their lead drug candidate DRT-101, which utilizes AI-enhanced protein structure generation to create a novel chimeric protein combining BMP7 and Activin proteins.
The technology has shown enhanced therapeutic efficacy and safety in studies conducted at UC San Diego between 2020-2024. This marks Darnatein's first international patent following their South Korean registration, with pending applications in the EU and US through the PCT route.
The global osteoarthritis treatment market, valued at $8.9 billion in 2023, is projected to reach $16.1 billion by 2032, growing at 7% annually. Darnatein aims to initiate Phase 1 clinical trials for DRT-101 later this year, targeting disease modification rather than just symptom management in osteoarthritis treatment.
Darnatein, una filiale di OSR Holdings (NASDAQ: OSRH), ha ottenuto un brevetto in Cina per la sua innovativa tecnologia di trattamento dell'osteoartrite basata su proteine. Il brevetto copre il loro principale candidato farmaco DRT-101, che utilizza la generazione di strutture proteiche potenziata dall'IA per creare una nuova proteina chimerica che combina le proteine BMP7 e Activin.
La tecnologia ha mostrato un'efficacia terapeutica e una sicurezza migliorate in studi condotti presso l'UC San Diego tra il 2020 e il 2024. Questo segna il primo brevetto internazionale di Darnatein dopo la registrazione in Corea del Sud, con domande pendenti nell'UE e negli Stati Uniti attraverso la via PCT.
Il mercato globale per il trattamento dell'osteoartrite, valutato 8,9 miliardi di dollari nel 2023, è previsto raggiungere 16,1 miliardi di dollari entro il 2032, crescendo del 7% annualmente. Darnatein mira a iniziare gli studi clinici di Fase 1 per DRT-101 entro la fine dell'anno, puntando alla modifica della malattia piuttosto che alla semplice gestione dei sintomi nel trattamento dell'osteoartrite.
Darnatein, una subsidiaria de OSR Holdings (NASDAQ: OSRH), ha obtenido una patente en China para su innovadora tecnología de tratamiento de la osteoartritis basada en proteínas. La patente cubre su principal candidato a fármaco DRT-101, que utiliza la generación de estructuras proteicas mejorada por IA para crear una nueva proteína quimérica que combina las proteínas BMP7 y Activin.
La tecnología ha mostrado una eficacia terapéutica y seguridad mejoradas en estudios realizados en UC San Diego entre 2020 y 2024. Esto marca la primera patente internacional de Darnatein tras su registro en Corea del Sur, con solicitudes pendientes en la UE y EE.UU. a través de la ruta PCT.
El mercado global de tratamientos para la osteoartritis, valorado en 8.9 mil millones de dólares en 2023, se proyecta que alcanzará 16.1 mil millones de dólares para 2032, creciendo a un 7% anual. Darnatein tiene como objetivo iniciar ensayos clínicos de Fase 1 para DRT-101 a finales de este año, enfocándose en la modificación de la enfermedad en lugar de solo el manejo de síntomas en el tratamiento de la osteoartritis.
다르나틴(Darnatein)은 OSR 홀딩스(OSR Holdings, NASDAQ: OSRH)의 자회사로, 중국에서 혁신적인 단백질 기반의 골관절염 치료 기술에 대한 특허를 확보했습니다. 이 특허는 인공지능(AI) 기반의 단백질 구조 생성을 활용하여 BMP7과 Activin 단백질을 결합한 새로운 키메라 단백질인 주요 약물 후보 DRT-101을 포함합니다.
이 기술은 2020년부터 2024년까지 UC 샌디에고에서 진행된 연구에서 향상된 치료 효능과 안전성을 보였습니다. 이는 다르나틴의 첫 번째 국제 특허로, 한국 등록 이후 유럽연합(EU)과 미국에서 PCT 경로를 통한 신청이 진행 중입니다.
2023년 89억 달러로 평가된 글로벌 골관절염 치료 시장은 2032년까지 161억 달러에 이를 것으로 예상되며, 연평균 7% 성장할 것으로 보입니다. 다르나틴은 올해 말 DRT-101에 대한 1상 임상 시험을 시작할 계획이며, 골관절염 치료에서 증상 관리뿐만 아니라 질병 수정에 초점을 맞추고 있습니다.
Darnatein, une filiale d'OSR Holdings (NASDAQ: OSRH), a obtenu un brevet en Chine pour sa technologie innovante de traitement de l'arthrose basée sur des protéines. Le brevet couvre leur principal candidat médicament DRT-101, qui utilise la génération de structures protéiques améliorée par IA pour créer une nouvelle protéine chimérique combinant les protéines BMP7 et Activin.
La technologie a montré une efficacité thérapeutique et une sécurité améliorées dans des études réalisées à l'UC San Diego entre 2020 et 2024. Cela marque le premier brevet international de Darnatein après son enregistrement en Corée du Sud, avec des demandes en attente dans l'UE et aux États-Unis via la voie PCT.
Le marché mondial des traitements de l'arthrose, évalué à 8,9 milliards de dollars en 2023, devrait atteindre 16,1 milliards de dollars d'ici 2032, avec une croissance annuelle de 7%. Darnatein vise à commencer des essais cliniques de phase 1 pour DRT-101 plus tard cette année, en ciblant la modification de la maladie plutôt que la simple gestion des symptômes dans le traitement de l'arthrose.
Darnatein, eine Tochtergesellschaft von OSR Holdings (NASDAQ: OSRH), hat ein Patent in China für ihre innovative, proteinbasierte Technologie zur Behandlung von Osteoarthritis gesichert. Das Patent deckt ihren führenden Arzneimittelkandidaten DRT-101 ab, der KI-gestützte Proteinstruktur-Generierung nutzt, um ein neuartiges chimäres Protein zu erzeugen, das BMP7- und Activin-Proteine kombiniert.
Die Technologie hat in Studien, die zwischen 2020 und 2024 an der UC San Diego durchgeführt wurden, eine verbesserte therapeutische Wirksamkeit und Sicherheit gezeigt. Dies markiert Darnateins erstes internationales Patent nach der Registrierung in Südkorea, mit ausstehenden Anträgen in der EU und den USA über den PCT-Weg.
Der globale Markt für Osteoarthritis-Behandlungen, der 2023 auf 8,9 Milliarden Dollar geschätzt wird, soll bis 2032 auf 16,1 Milliarden Dollar anwachsen, mit einer jährlichen Wachstumsrate von 7%. Darnatein plant, noch in diesem Jahr klinische Phase-1-Studien für DRT-101 zu starten, mit dem Ziel, die Krankheit zu modifizieren, anstatt nur die Symptome bei der Behandlung von Osteoarthritis zu verwalten.
- Secured strategic patent in China, world's largest market, expanding IP protection
- Demonstrated enhanced efficacy and safety in preclinical studies (2020-2024)
- Targeting $16.1B market opportunity by 2032
- Novel disease-modifying approach vs. current symptom-only treatments
- Phase 1 clinical trials planned for 2025
- Product still in preclinical stage, years away from potential commercialization
- Will face significant competition in growing osteoarthritis market
- Success in clinical trials not guaranteed despite preclinical results
Insights
OSR Holdings' subsidiary Darnatein has significantly strengthened its intellectual property position by securing a Chinese patent for its Activin/BMP7 chimeric protein technology, following earlier protection in South Korea. This represents a strategic expansion of their IP fortress for DRT-101, their lead osteoarthritis drug candidate.
The China approval is particularly valuable for three reasons: (1) it protects a novel AI-enhanced protein design approach in one of the world's largest pharmaceutical markets, (2) it comes as China faces rapidly rising osteoarthritis prevalence due to population aging, and (3) it creates barriers to entry in a market projected to grow from
What distinguishes this technology is its disease-modifying approach. Current osteoarthritis treatments merely address symptoms through painkillers and anti-inflammatories, while Darnatein's chimeric protein technology potentially targets the underlying disease mechanism. This positions DRT-101 in the highly sought-after DMOAD (Disease-Modifying Osteoarthritis Drug) category that could command premium pricing and partnership interest from major pharmaceutical companies seeking to expand beyond symptom management.
The validation from UCSD preclinical studies (2020-2024) showing enhanced efficacy and safety provides substantiation for the technology approach. With preclinical studies nearing completion and Phase 1 trials targeted for later this year, this patent represents critical protection during the most valuable development phase when the company might attract licensing interest.
The Chinese patent approval for Darnatein's chimeric protein technology marks a crucial milestone in OSR Holdings' commercialization strategy. This IP expansion creates three distinct value drivers for the
- Strategic positioning for eventual entry into China's rapidly growing osteoarthritis market
- Enhanced attractiveness for potential licensing deals with global pharmaceutical partners
- Protection of a novel therapeutic approach as they near clinical-stage development
The timing is particularly advantageous as Darnatein prepares for Phase 1 trials while building a global patent portfolio covering key markets (South Korea, China, with EU and US pending). This methodical approach to IP protection demonstrates management's strategic focus on maximizing the technology's commercial potential before significant clinical spending begins.
While still in preclinical development, DRT-101's disease-modifying approach represents the direction the entire field is moving - away from symptom management toward addressing underlying disease mechanisms. This alignment with industry priorities increases the probability of attracting development partners who can accelerate commercialization.
The AI-enhanced protein design platform creates additional optionality beyond DRT-101, as the company mentions potential applications for other musculoskeletal disorders. This suggests the core technology could generate multiple therapeutic candidates, creating a pipeline from a single platform - an efficiency that sophisticated biotech investors particularly value.
Activin/BMP7 Chimera Protein Technology Registered in
Darnatein has officially registered a patent with the China National Intellectual Property Administration (CNIPA) for the core technology behind its break-through disease-modifying osteoarthritis drug (DMOAD) lead drug candidate, DRT-101. Following the national registration of the patent in
The technology basis is an AI-enhanced innovative protein structure generator designed to provide therapeutics that overcome the current limitations of standard of care treatment in osteoarthritis—a condition for which only symptom management options currently exist. This technology represents a wholly new approach to protein design and is expected to address the underlying causes of disease. This treatment approach may significantly improve treatment outcomes not only for osteoarthritis but also for a wide range of other musculoskeletal disorders.
In particular, the DRT-101 chimeric protein, which recombines the natural BMP7 and Activin proteins into a wholly novel structure, has already been shown to enhance both therapeutic efficacy and safety in vivo, in studies conducted between 2020 and 2024 at the University of
Senyon Choe, Darnatein Chief Executive Officer, stated, "The protein design technology now also patented in
Constance Höfer, Chief Scientific Officer of OSR Holdings, stated, "Darnatein's groundbreaking technology represents a wholly new, AI-enhanced approach to therapeutic protein design. The successful patent registration in
Global Technological Competitiveness and Licensing Potential
The osteoarthritis treatment market continues to grow, due to globally aging populations. In 2023, the market size reached approximately
Industry experts have remarked, "Darnatein's Activin/BMP7 chimera technology offers a superior profile to be developed into a potential DMOAD, or disease-modifying OA drug, compared to existing standard of care for osteoarthritis treatments," adding, "Big Pharma is looking for novel treatments that can slow, stop, or even reverse the cartilage degeneration and joint damage that occurs with OA. On this backdrop, Darnatein's chimeric protein approach represents a paradigm shift away from only symptom relief (e.g. painkillers and anti-inflammatories) to treatment options targeting the underlying pathobiology of OA"
Darnatein is currently completing preclinical studies with DRT-101, its degenerative OA treatment candidate, with the goal to initiate Phase 1 clinical trials later this year.
About Darnatein
Founded in 2012, Darnatein is a biotherapeutics company based in
About OSR Holdings, Inc.
OSR Holdings, Inc. is a global healthcare company dedicated to advancing biomedical innovation. Through its subsidiaries, OSR is engaged in oncology immunotherapies, degenerative disease biologics, and medical device distribution. OSR's vision is to acquire and operate a portfolio of innovative healthcare companies, improving patient care through cutting-edge research and development. For more information, visit www.OSR-Holdings.com.
Contact
View original content to download multimedia:https://www.prnewswire.com/news-releases/darnatein-an-osr-company-broadens-intellectual-property-protection-for-innovative-osteoarthritis-treatment-technology-302424483.html
SOURCE OSR Holdings Inc.
FAQ
What is the market potential for OSRH's osteoarthritis treatment technology?
When will OSRH's DRT-101 begin clinical trials?
What makes OSRH's DRT-101 different from existing osteoarthritis treatments?
Which patents has OSRH secured for its osteoarthritis treatment technology?
What are the clinical results of OSRH's DRT-101 so far?
